Sales of the lymphoma drug Monjuvi continue to underwhelm but MorphoSys believes that its investigational BET inhibitor, pelabresib, can become a standard of care for the rare bone marrow disease myelofibrosis.

Plus deals involving Santen/Harrow/Visiox, Aurobindo/BioFactura, AFT/Crossject, Imugene/RenovoRx, Biotheus/BioNTech, GeneQuantum/InxMed, ObsEva/Yuyuan, Monopar/National University of Singapore and Doer Biologics/BioNTech.

The German biotech has highlighted its myelofibrosis drug candidate, pelabresib, as a key value driver going forward after a year of hard knocks and lackluster Monjuvi sales that forced the firm to downsize its workforce and cease preclinical operations.

The German biotech announced in March that it was terminating the early-stage oncology R&D projects that came with its purchase of Constellation last year and Novartis has snapped up one of them.